Home  /  Resource Library  /  Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

Polatuzumab Vedotin Plus Venetoclax with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Primary Efficacy Analysis of a Phase Ib/II Study

ASH 2020: Preliminary results of a phase II trial investigating polatuzumab vedotin combined with venetoclax and rituximab for treatment of relapsed DLBCL.